Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Nintedanib (VARGATEF and generics), ATC L01EX09 for the period 01.05.26-30.04.28 (plus extension option 1x12 months)
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Nintedanib (VARGATEF und Generika), ATC L01EX09 für die Zeit 01.05.26-30.04.28 (zzgl. V.-Option 1x12 Monate)
Germany
Contract
BuyerDAK-Gesundheit
TypeSupplies
Estimated valuevalue not published
Published15 March 2026
CategoryMedical equipment & pharma · CPV 33000000
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Abacus Medicine A/S · Kopenhagen | 172 | 2022–2026 |
| kohlpharma GmbH · Merzig | 157 | 2022–2026 |
| EurimPharm Arzneimittel GmbH · Saaldorf-Surheim | 126 | 2022–2026 |
| CC Pharma GmbH · Densborn | 121 | 2022–2025 |
| Orifarm GmbH · Leverkusen | 113 | 2015–2025 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.
How often this buyer tenders this
2019260
2020167
2021201
2022187
2023291
2024654
20251,183
20259
2026739
Who knows the rhythm prepares instead of reacting.
929
days until the deadline — Monday 5 March at 10:00
How to bid
Read the full notice — Original + documents
Goes directly to this tender on Vergabemarktplatz (cosinex). The full specification and all annexes are there.
Tenders like this, every morning at 7:30 in your inbox.
Start free →